Loading
Intracavitary immunotherapy targets cancer that coats the lining of the abdomen or chest, which drugs given by drip barely reach. Delivering it straight into the cavity gives far higher local doses.
Peritoneal and pleural surface disease has poor drug penetration from the circulation, which is why intraperitoneal chemotherapy and pressurised aerosol delivery persist despite mixed evidence. Regional immunotherapy (intraperitoneal interleukin-2, checkpoint antibodies, T-cell engagers or CAR-T cells) reaches high local concentrations, and intrapleural mesothelin CAR-T has shown feasibility. The unresolved questions are dosing, drainage-related loss and cytokine toxicity.
Two bottleneck pages and 32 idea pages on OnCo cite this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing pages listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
One of the most cited reviews Europe PMC returns for Mesothelin in Mesothelioma, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
One of the most cited reviews Europe PMC returns for Mesothelin in Mesothelioma, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
One of the most cited reviews Europe PMC returns for Mesothelin in Mesothelioma, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
Shares Mesothelin Immunotherapy for Cancer: Ready for Prime Time?, Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors, Mesothelin: a new target for immunotherapy, Mesothelin.
Shares Peritoneal metastasis, HIPEC / PIPAC (intraperitoneal chemotherapy), Metastasis is understood least and studied last, Gastric & gastro-oesophageal junction cancer.
Shares Mesothelin, Mesothelioma, Immune checkpoint inhibitors.
Shares Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs, Cold tumours and the immunosuppressive microenvironment, Immune checkpoint inhibitors.
Shares HIPEC / PIPAC (intraperitoneal chemotherapy), Gastric & gastro-oesophageal junction cancer, Ovarian cancer.
Shares Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs, Cold tumours and the immunosuppressive microenvironment, Immune checkpoint inhibitors.
Shares Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs, Cold tumours and the immunosuppressive microenvironment, Immune checkpoint inhibitors.
Shares Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs, Cold tumours and the immunosuppressive microenvironment, Immune checkpoint inhibitors.